Paola Ghione

Oncology
1275 York Ave
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 83 publications

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Journal: Haematologica
Published: March 06, 2026

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Journal: Blood advances
Published: February 24, 2026

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Journal: Blood advances
Published: January 05, 2026

Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5.

Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5.

Journal: Leukemia & lymphoma
Published: December 30, 2025

Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targets.

Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targets.

Journal: Haematologica
Published: October 23, 2025

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Journal: Blood
Published: September 02, 2025

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

Journal: Blood
Published: August 20, 2025

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

Journal: Blood
Published: August 20, 2025

Cumulative incidence and factors associated with subsequent myeloid neoplasms in patients with nodal T-follicular helper cell lymphomas.

Cumulative incidence and factors associated with subsequent myeloid neoplasms in patients with nodal T-follicular helper cell lymphomas.

Journal: Haematologica
Published: July 03, 2025

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.

Journal: Leukemia & lymphoma
Published: July 02, 2025
Showing 1-12 of 83

Last Updated: 09/26/2026